Dihydroergotamine methanesulfonate
Dihydroergotamine methanesulfonate Brand names, Dihydroergotamine methanesulfonate Analogs
- Agit
- Angionorm
- D.H.E.
- D.H.E. 45
- DET MS
- DHE-45
- Dergotamine
- Diergo
- Dihidroergotamina [INN-Spanish]
- Dihydergot
- Dihydroergotamine mesylate
- Dihydroergotamine methanesulfonate
- Dihydroergotamine monomethanesulfonate
- Dihydroergotaminum [INN-Latin]
- Dirgotarl
- Endophleban
- Ergomimet
- Ergont
- Ergotamine, 9,10-dihydro-
- Ergotonin
- Ikaran
- Migranal
- Morena
- Orstanorm
- Tonopres
- Verladyn
Dihydroergotamine methanesulfonate Brand Names Mixture
- No information avaliable
Dihydroergotamine methanesulfonate Chemical_Formula
C33H37N5O5
Dihydroergotamine methanesulfonate RX_link
http://www.rxlist.com/cgi/generic2/dihyergmes.htm
Dihydroergotamine methanesulfonate fda sheet
Dihydroergotamine methanesulfonate msds (material safety sheet)
Dihydroergotamine methanesulfonate Synthesis Reference
No information avaliable
Dihydroergotamine methanesulfonate Molecular Weight
583.678 g/mol
Dihydroergotamine methanesulfonate Melting Point
No information avaliable
Dihydroergotamine methanesulfonate H2O Solubility
No information avaliable
Dihydroergotamine methanesulfonate State
Solid
Dihydroergotamine methanesulfonate LogP
No information avaliable
Dihydroergotamine methanesulfonate Dosage Forms
Liquid
Dihydroergotamine methanesulfonate Indication
For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
Dihydroergotamine methanesulfonate Pharmacology
Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.
Dihydroergotamine methanesulfonate Absorption
Interpatient variable and may be dependent on the administration technique
Dihydroergotamine methanesulfonate side effects and Toxicity
Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting
Dihydroergotamine methanesulfonate Patient Information
PATIENT INFORMATIOn
Follow the link below to get detailed information before taking D.H.E. 45� (dihydroergotamine mesylate) Injection.
http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm
Follow the link below to get detailed information before taking D.H.E. 45� (dihydroergotamine mesylate) Injection.
http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm
Dihydroergotamine methanesulfonate Organisms Affected
Humans and other mammals
